Meeting
2022 ASCO Annual Meeting
Actual immune checkpoint inhibitor drug use in U.S. patients with cancer.
Authors
Alia Rawji
OptumLabs, Minnetonka, MN
Alia Rawji , Henry J. Henk , Stacey DaCosta Byfield , Jennifer Malin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2608)
DOI
10.1200/JCO.2022.40.16_suppl.2608
Abstract #
2608
Poster Bd #
263
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Duration of first-line immune checkpoint inhibitor treatment in U.S. patients with melanoma, non–small cell lung cancer, and renal cell carcinoma.
First Author: Alia Rawji
Poster
2023 ASCO Annual Meeting
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
First Author: Minh Duc Phan
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
First Author: Nathaniel R. Wilson
Poster
2022 ASCO Annual Meeting
Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
First Author: Christian Grohé